Table 3.
Outcomes in the study population.*
| Case # |
Acute locally recurrent DVT within 7d of procedure,† and status on repeat procedure (re-lysed vs. refractory) |
Follow-up duration at last clinic visit (mo) |
Non- acute recurrent VTE, and type (local vs. distant) |
Time from procedure to dx of non-acute recurrent VTE (mo) |
Any PTS at 1–2 y |
Physically and functionally significant PTS at 1–2 y |
Basic CEAP findings |
Wong- Baker chronic pain findings |
|---|---|---|---|---|---|---|---|---|
| 1 | None | 12 | Yes (distant) |
4.5 | Yes | n/a | C | n/a (pre- morbid chronic pain) |
| 2 | None | 42 | None | n/a | Yes | No | None | AA, ADL |
| 3 | Yes (re-lysed) |
36 | Yes (local) |
0.5 | Yes | No | None | AA |
| 4 | Yes (re-lysed) |
27 | Yes (local) |
14 | Yes | Yes | E | AA, ADL |
| 5 | None | 30 | None | n/a | Yes | No | None | AA |
| 6 | None | 24 | None | n/a | No | No | None | None |
| 7 | Yes (re-lysed) |
2 | None | n/a | n/a | n/a | n/a | n/a |
| 8 | Yes (re-lysed§) |
14 | Yes (distant) |
3–12 mo (asymptomatic) |
No¶ | No | None | None |
| 9 | None | 26 | Yes (local) |
1–3 mo (asymptomatic) |
Yes | No | E | None |
| 10 | None | 14 | None | n/a | Yes | No | E | None |
| 11 | None | 18 | Yes (local) |
2 mo | Yes | No | None | AA, rest |
| 12 | None | 6 | None | n/a | n/a | n/a | n/a | n/a |
| 13 | None | 10 | Yes (local) |
9 mo | n/a | n/a | n/a | n/a |
| 14 | None | 3 | None | n/a | n/a | n/a | n/a | n/a |
| 15 | Yes (re-lysed§) |
1 | None | n/a | n/a | n/a | n/a | n/a |
| 16 | None | 6 | None | n/a | n/a | n/a | n/a | n/a |
Abbreviations: DVT=deep venous thombosis; PE=pulmonary embolism; PTS=post-thrombotic syndrome; CEAP= Basic Clinical-Etiologic-Anatomic-Pathophysiologic (American Venous Forum) physical exam component of the Manco-Johnson pediatric PTS instrument; W-B: Wong-Baker “faces” chronic pain
There were no major bleeding events, and one symptomatic pulmonary embolism, within 7 days of procedure.
Includes isolated stent thrombosis.
Reliability of assessment of basic CEAP component on contralateral difference in limb circumference may be limited due to bilaterality of DVT at presentation.
Recurred twice in these subjects with multiple-antibody APS with thrombotic storm. Patency was eventually maintained post-MT/PMT in each patient only after multi-modal immunomodulatory therapy had been instituted and potent direct thrombin inhibition had resulted in marked decrease in D-dimer.